TTF-1
in extra-pulmonary adenocarcinoma (excluding thyroid neoplasms)
Note that the data listed in this table is,
where stated, for clone 8G7G3/1 or for polyclonal antibody. For
the lower specificity of clone SPT24, see TTF-1
monoclonal comparison.
Breast |
4/551 (0/965,
0/1815, 0/5(using clone 8G7G3/1,
signet ring cell carcinomas)19,
0/7(using
monoclonal 8G7G3/1)23,
0/5(antibody
from Neomarkers, Fremont CA, therefore presumably clone 8G7G3/1:
metastases to brain)34,
0/10(using
monoclonal 8G7G3/1)6,
0/13(using
clone 8G7G3/1)7,
0/8(cell
blocks from cases with metastatic adenocarcinoma to serous cavities,
using clone 8G7G3/1)9,
0/51(using
a polyclonal antibody)1,
0/2(lung
metastasis, using clone 8G7G3/1)8,
0/25(using
clone 8G7G3/1)35,
0/11(antibody
from NeoMarkers, Fremont, CA, therefore presumably 8G7G3/1)39, 0/6(metastatic
tumour, using cytological cell blocks)43,
0/6(breast
adenocarcinoma metastatic to brain)44,
0/6(lung
metastasis, using clone 8G7G3/1)10,
0/12(using
cell blocks from tumour in serous effusions)45, 0/4(using
8G7G3/1, metastatic to cervical lymph node)46, 0/24(using
cytospin preparations from body cavity fluids)47, 0/12(using
8G7G3/1, tumours metastatic to lung)48,
0/11(said
to have used SG7G3/1 and a cell transfer technique on serous effusion
specimens)49,
0/12(metastatic
to brain)49,
0/35(said
to have used clone SPT249!) 50, 0/5(using
8G7G3/1)52,
0/3053, 4/5(using Dako antibody)56, 0/17(using
TMAs and clone 8G7G3/1)57,
0/115(91
ductal, 24 lobular)58),
13/546(Clone
SPT24, and Envision+ detection system: expression diffuse and
strong in 3 casaes, focal and weak in 8 cases)61, 0/30(using
clone 8G7G3/1: invasive ductal carcinomas)62, 0/14(using
clone 8G7G3/1: invasive non-small cell neuroendocrine carcinomas;
5 so-called carcinoid tumors, 2 neuroendocrine carcinomas not-otherwise-
specified, 2 invasive ductal carcinomas with neuroendocrine features,
1 invasive lobular carcinoma
with neuroendocrine features, and 4 type B colloid carcinomas)62 |
Salivary
gland |
0/3(metastases
to brain)23 |
Gastrointestinal
tract |
0/12(using
cell blocks from tumour in serous effusions)45, 0/16(using
cytospin preparations from body cavity fluids)47, 0/14(metastatic
to lung)48, 0/6(metastatic
to brain)49 |
Oesophagus |
0/315, 0/21(said
to have used clone SPT249!) 50 |
Stomach |
3/188 (1/661,
0/315, 0/5(using clone 8G7G3/1,
signet ring cell carcinomas) 19,
0/24(using
clone 8G7G3/1)31,
0/2(using
clone 8G7G3/1)7,
0/9(cell
blocks from cases with metastatic adenocarcinoma to serous cavities,
using clone 8G7G3/1)9,
1/2339, 0/11(using a cell transfer
technique on serous effusion specimens)49,
1/34(said
to have used clone SPT249!) 50, 0/1152) |
Colon |
4/476 ( 0/18(primary
tumours, using polyclonal antibody)1, 0/21(primary tumours, using
clone 8G7G3/1)2,
0/30(primary
tumours, using clone 8G7G3/1)4
, 0/20(primary
tumours, using clone 8G7G3/1)6, 0/26(primary tumours, using
clone 8G7G3/1)7,
0/3(lung
metastasis, using clone 8G7G3/1)8,
0/8(cell
blocks from cases of metastatic carcinoma to serous cavities,
using clone 8G7G3/1)9,
0/6(lung
metastasis, using clone 8G7G3/1)10,
0/5(lung
metastasis, using clone 8G7G3/1)11,
0/26(lung
metastasis, using clone 8G7G3/1)12,
0/5(using
clone 8G7G3/1, signet ring cell carcinomas) 19,
0/1(metastases
to brain)23,
0/35(using
clone 8G7G3/1)31,
0/16(using
clone 8G7G3/1)34,
0/10(using
clone 8G7G3/1)35,
0/25(NeoMarkers, Fremont, CA)39, 0/50(using
clone 8G7G3/1)40,
0/1(colonic
adenocarcinoma metastatic to brain)44,
0/2(using
a cell transfer technique on serous effusion specimens)49, 0/47(said
to have used clone SPT249!) 50, 0/252,
0/5(using
TMAs and clone 8G7G3/1)57
, 4/14(using
clone 8G7G3/1: positive in 2 of 7 metastases to lung; one of the
two primary tumours was also positive and in 2 of 7 metastases
to liver; both primary tumours were also positive)59, 0/100(using
clone 8G7G3/1: primary tumours examined as TMA)59) |
Liver |
0/22(using
monoclonal 8G7G3/1)6,
0/2(lung
metastasis, using clone 8G7G3/1)8,
0/1 (metastatic
to cervical lymph node)46, 0/1(using
a cell transfer technique on serous effusion specimens)49, 0/6(said
to have used clone SPT249!) 50, 0/152 |
Gallbladder |
0/115, 0/10(NeoMarkers,
Fremont, CA)39,
0/1(lung
metastasis, using clone 8G7G3/1)10,
0/10(said
to have used clone SPT249!) 50 |
Ampulla
of Vater |
0/6(said
to have used clone SPT249!) 50 |
Pancreas |
0/108 (0/215,
0/7(using
clone 8G7G3/1)31,
0/15(NeoMarkers,
Fremont, CA)39,
1/53(said
to have used clone SPT249!) 50, 0/31(using
TMAs and clone 8G7G3/1)57) |
Genitourinary
tract |
0/34(using
cytospin preparations from body cavity fluids)47 |
Kidney |
0/86 (0/185,
0/14(metastases
to brain)23,
0/9(using
clone 8G7G3/1)34,
0/7(using
clone 8G7G3/1) 7,
0/8(using
a polyclonal antibody) 1,
0/2(lung
metastasis, using clone 8G7G3/1) 8,
0/10(using
clone 8G7G3/1) 35,
0/1(renal
carcinoma metastatic to brain) 44,
0/2(lung
metastasis, using clone 8G7G3/1)10,
0/1550,
0/118(using
TMAs and clone 8G7G3/1:
0/41 clear cell, 0/43 papillary, 0/34 chromophobe)57) |
Bladder |
0/3(lung
metastasis, using clone 8G7G3/1)10 |
Ovary |
29/556 (0/305,
1/16(few
very weakly reactive cells)15,
0/15(using
clone 8G7G3/1)31,
15/53(endometrioid: 3/8,
serous: 6/25; strong in one case, clear cell: 4/10; strong in
two cases, mucinous: 2/10; strong in one case)33, 0/2(using
clone 8G7G3/1)34,
0/15(cell
blocks from cases with metastatic adenocarcinoma to serous cavities,
using clone 8G7G3/1)9,
0/4(lung
metastasis, using clone 8G7G3/1)8,
0/30(using
clone 8G7G3/1)35,
2/166(strong
nuclear staining in one mixed serous and endometrioid carcinoma
and one serous carcinoma: in the latter, staining was confined
to poorly differentiated areas. The other 50 serous, 30 endometrioid,
23 mucinous, 30 clear cell, 24 mixed epithelial, and 7 mixed mixed
Mullerian tumours were all negative. Staining was done using clone
8G7G3/1)36,
9/34(using
whole tissue sections any staining was usually focal; 7 of 19
serous carcinomas (diffuse in one serous carcinoma), 1 of 5 endometrioid
adenocarcinomas, diffuse 1 of 3 clear cell carcinomas and 0 of
7 mucinous tumours.)42,
2/138(using
tissue microarrays; 2 of 65 endometrioid adenocarcinomas, 0 of
35 mucinous adenocarcinomas, 0 of 30 mucinous neoplasms of low
malignant potential, and 0 of 10 clear cell carcinoma)42, 0/12(using
cell blocks from tumour in serous effusions)45, 0/1(metastatic
to cervical lymph node)46, 0/6
(using a cell transfer technique on serous effusion specimens)49, 0/28(10
serous, 18 mucinous)50, 0/652) 1/1(malignant
mixed Mullerian tumour)55 |
Endometrium |
7/97 (1/81,
0/415, 0/25(using clone 8G7G3/1)31, 0/3(using
clone 8G7G3/1)34,
0/1(using
monoclonal 8G7G3/1)6,
0/6(lung
metastasis, using clone 8G7G3/1)8,
6/32(endometrioid
carcinomas: positivity in 1/11 grade I, 2/8 grade 2 and 3/13 grade
III: in 5 cases the positivity was demonstrated with 8G7G3/1,
in 1 case with SPT24: 2 cases showed positivity of 50-75% of nuclei)37, 3/13(serous
carcinomas: with one case showing positivity of >75% of nuclei:
positivity was with clone SPT24)37,
0/1(lung
metastasis, using clone 8G7G3/1)10,
0/10(said
to have used clone SPT249!) 50), 1(case report)54, 1/67(using
TMA and clone 8G7G3/1: 0/49 endometrioid, 1/18 papillary serous
carcinoma)60
|
Cervix
uteri |
1/28(The
positive case was poorly differentiated, showing positivity of
50-75% of nuclei using clone 8G7G3/1: this positive case was also
positive for p16)37,
0/44(using
TMA and clone 8G7G3/1: 0/8 in situ adenocarcinomas, 0/36 invasive
carcinomas)60
|
Peritoneal
serous carcinoma |
1/1338 |
Prostate |
0/56 (0/195,
0/215, 0/9(using a polyclonal
antibody)1, 0/1(lung
metastasis, using clone 8G7G3/1)8,
0/10(using
clone 8G7G3/1)35,
0/15(NeoMarkers,
Fremont, CA)39,
2/29(positivity
was seen in areas of mucinous differentiation)41,
0/1 (prostatic
adenocarcinoma metastatic to brain)44,
0/1(metastatic
to cervical lymph node)46, 2/18(said
to have used clone SPT249!) 50, 1(case report of a ductal
carcinoma positive using SPT24)51) |
paranasal
sinus |
0/1 (paranasal
adenocarcinoma metastatic to brain)44 |
Total |
18/534 (2/2865, 1/4915, 0/1519, 0/2523, 0/106(using clone 8G7G3/1)31, 15/5333) |
15using
cell blocks from FNAs
I have seen one focally positive colorectal metastasis
to lung (unpublished case).
References
2Holzinger
A, Dingle S, Bejarano PA, et al. Monoclonal antibody to thyroid transcription
factor-1: production, characterization, and usefulness in tumor diagnosis.
Hybridoma 1996; 15:49-53
3 Ordonez
NG. Value of thyroid transcription factor-1 immunostaining in distinguishing
small cell lung carcinomas from other small cell carcinomas. Am J Surg
Pathol 2000; 24:1217-23
4 Kaufmann
O,Dietel M Thyroid transcription factor-1 is the superior immunohistochemical
marker for pulmonary adenocarcinomas and large cell carcinomas compared
to surfactant proteins A and B. Histopathology 2000; 36:8-16
5
Ordonez NG. Thyroid transcription factor-1 is a marker
of lung and thyroid carcinomas. Advances in Anatomic Pathology 2000; 7(2):
123-127.
6
Chang
YL, Lee YC, Liao WY, et al. The utility and limitation of thyroid transcription
factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer
2004; 44:149-57
7
Moldvay
J, Jackel M, Bogos K, et al. The role of TTF-1 in differentiating primary
and metastatic lung adenocarcinomas. Pathol Oncol Res 2004; 10:85-8
8
Reis-Filho
JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker
to distinguish primary from metastatic lung adenocarcinomas? Pathol Res
Pract 2000; 196:835-40
9
Jang
KY, Kang MJ, Lee DG, et al. Utility of thyroid transcription factor-1
and cytokeratin 7 and 20 immunostaining in the identification of origin
in malignant effusions. Anal Quant Cytol Histol 2001; 23:400-4
10
Chhieng
DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor
1, PE-10, and cytokeratins 7 and 20 in discriminating between primary
lung carcinomas and metastatic lesions in fine-needle aspiration biopsy
specimens. Cancer 2001; 93:330-6 FULL TEXT
11
Ng
WK, Chow JC,Ng PK Thyroid transcription factor-1 is highly sensitive and
specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma
in effusion fluid cytology specimens. Cancer 2002; 96:43-8
12
Wieczorek
TJ, Pinkus JL, Glickman JN, et al. Comparison of thyroid transcription
factor-1 and hepatocyte antigen immunohistochemical analysis in the differential
diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal
cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol 2002;
118:911-21
15
Hecht, J. L., Pinkus,
J. L., Weinstein, L. J., Pinkus, G. S. The value of thyroid transcription
factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma
of lung origin Am J Clin Pathol 2001;116:483-488.
19
Merchant,
S.H., Amin, M.B., Tamboli, P., Ro, J., Ordonez, N.G., Ayala, A.G., Czerniak,
B.A. and Ro, J.Y. Primary signet-ring cell carcinoma of lung: immunohistochemical
study and comparison with non-pulmonary signet-ring cell carcinomas. Am
J Surg Pathol 2001;25:1515-9.
23 Srodon,
M. and Westra, W.H. Immunohistochemical staining for thyroid transcription
factor-1: a helpful aid in discerning primary site of tumor origin in
patients with brain metastases. Hum Pathol 2002;33:642-5.
31
Stenhouse, G., N.
Fyfe, et al. (2004). "Thyroid transcription factor 1 in pulmonary
adenocarcinoma." J Clin Pathol 57(4): 383-7.
33
Quddus MR et al. Expression of TTF-1 in primary ovarian surface epithelial
carcinomas: a study of 53 cases. Modern Pathology 2004 17(1):211A.
34 Jerome
Marson, V., J. Mazieres, et al. (2004). "Expression of TTF-1 and
cytokeratins in primary and secondary epithelial lung tumours: correlation
with histological type and grade." Histopathology 45(2): 125-34.
35 Ordonez
NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and
CD44S immunostaining in distinguishing epithelial pleural mesothelioma
from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;
24:598-606.
36 Graham
AD, Williams AR,Salter DM TTF-1 expression in primary ovarian epithelial
neoplasia. Histopathology 2006; 48:764-5
37 Siami
K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression
in endometrial and endocervical adenocarcinomas. Am J Surg Pathol 2007;
31:1759-63 (published data suplemented with information kindly provided
by Dr Deavers)
38 Barnetson
RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal
mesothelioma and primary and secondary serous carcinoma of the peritoneum:
antibodies to estrogen and progesterone receptors are useful. Am J Clin
Pathol 2006; 125:67-76 CHECK
39 Nakamura
N, Miyagi E, Murata S, et al. Expression of thyroid transcription factor-1
in normal and neoplastic lung tissues. Mod Pathol 2002; 15:1058-67
40 Park
SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help
determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab
Med 2007; 131:1561-7 FULL TEXT
41 Leite
KR, Mitteldorf CA, Srougi M, et al. Cdx2, cytokeratin 20, thyroid transcription
factor 1, and prostate-specific antigen expression in unusual subtypes
of prostate cancer. Ann Diagn Pathol 2008; 12:260-6
42 Kubba
LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression
in ovarian epithelial neoplasms. Mod Pathol 2008; 21:485-90
43 Harlamert
HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins
7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998; 42:1382-8
44 Bohinski
RJ, Bejarano PA, Balko G, et al. Determination of lung as the primary
site of cerebral metastatic adenocarcinomas using monoclonal antibody
to thyroid transcription factor-1. J Neurooncol 1998; 40:227-31
45Afify
AM,al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1
expression in adenocarcinomas presenting in serous fluids. Acta Cytol
2002; 46:675-8
46
Roh
MS,Hong SH. Utility of thyroid transcription factor-1 and cytokeratin
20 in identifying the origin of metastatic carcinomas of cervical lymph
nodes. J Korean Med Sci 2002; 17:512-7 FULL TEXT
47
Gomez-Fernandez
C, Jorda M, Delgado PI, et al. Thyroid transcription factor 1: a marker
for lung adenoarinoma in body cavity fluids. Cancer 2002; 96:289-93
48
Su
YC, Hsu YC,Chai CY. Role of TTF-1, CK20, and CK7 immunohistochemistry
for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung
J Med Sci 2006; 22:14-9 FULL TEXT
49
Strickland-Marmol
LB, Khoor A, Livingston SK, et al. Utility of tissue-specific transcription
factors thyroid transcription factor 1 and Cdx2 in determining the primary
site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med 2007;
131:1686-90 FULL TEXT
50
Dennis
JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic
of the site of origin: development of a diagnostic algorithm. Clin Cancer
Res 2005; 11:3766-72 FULL TEXT
51
Lim
TK, Teo C, Giron DM, et al. Thyroid transcription factor-1 may be expressed
in ductal adenocarcinoma of the prostate:a potential pitfall. J Clin Pathol
2007; 60:941-3
52
Jan
IS, Chung PF, Weng MH, et al. Utility of thyroid transcription factor-1
expression in the differential diagnosis of metastatic adenocarcinoma
of serous effusion specimens prepared using the cell transfer technique.
J Formos Med Assoc 2006; 105:695-700
53 Bisceglia
M, Ragazzi M, Galliani CA, et al. TTF-1 expression in nephroblastoma.
Am J Surg Pathol 2009; 33:454-61
54 Deavers
MT Immunohistochemistry in gynecologic pathology. Arch Pathol Lab Med
2008; 132:175-80 FULL TEXT
55 Agaimy
A,Wunsch PH. Unexpected and potentially misleading TTF-1 expression: a
word of caution. Virchows Arch 2006; 449:603-5
56 Yamamoto
J, Ohshima K, Nabeshima K, et al. Comparative study of primary mammary
small cell carcinoma, carcinoma with endocrine features and invasive ductal
carcinoma. Oncol Rep 2004; 11:825-31
57 Bishop
JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression
in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and
malignant mesothelioma. Hum Pathol. 2010 Jan;41(1):20-5. (TTF-1 clone
8G7G3/1 used, confirmed by author)
59 Xu
B, Thong N, Tan D, Khoury T. Expression of thyroid transcription factor-1
in colorectal carcinoma. Appl Immunohistochem Mol Morphol. 2010 May;18(3):244-9.
60 Alkushi
A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, et al. Immunoprofile of
cervical and endometrial adenocarcinomas using a tissue microarray. Virchows
Arch. 2003 Mar;442(3):271-7.
61 Robens
J, Goldstein L, Gown AM, Schnitt SJ. Thyroid transcription factor-1 expression
in breast carcinomas. Am J Surg Pathol. 2010 Dec;34(12):1881-5.
62 Bisceglia
M, Galliani C, Rosai J. TTF-1 expression in breast carcinoma-the chosen
clone matters. Am J Surg Pathol. 2011 Jul;35(7):1087-8.
This page last
revised 28.11.2011.
©SMUHT/PW
Bishop